US Bancorp’s Beta Bionics BBNX Stock Holding History

US Bancorp’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.05K	Buy	450 +229	+104%	+$2.72K	﹤0.01%	3564
2026 Q1	$2.21K	Buy	221 +192	+662%	+$2.84K	﹤0.01%	3779
2025 Q4	$884	Buy	+29	New	+$774	﹤0.01%	3872

Other funds holding BBNX

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

US Bancorp's BBNX Position: Q2 2026 in Review

US Bancorp increased its Beta Bionics (BBNX) stake by 104% in Q2 2026, buying an estimated $2.72K and bringing the position to 450 shares worth $7.05K. The position accounts for ﹤0.01% of the portfolio, ranked #3564.

US Bancorp first reported a position in BBNX in Q4 2025 and has held it in 3 quarters since. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

US Bancorp held 450 shares of Beta Bionics worth $7.05K as of Q2 2026.
US Bancorp bought 229 Beta Bionics shares in Q2 2026, an estimated $2.72K.
Beta Bionics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3564 holding.
US Bancorp first reported a position in Beta Bionics in Q4 2025 and has held it in 3 quarters since.
133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.